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Eclampsia
Eclampsia is the association of convulsions or coma
with hypertension and proteinuria (preeclampsia) dur-
ing the second half of pregnancy or the early
puerperium. It causes significant maternal and perina-
tal morbidity and mortality. As a medical student, I was
taught that eclampsia represented a “grievous failure
of antepartum care.” Antepartum (or prenatal) care was
advocated nearly a century ago for the purpose of de-
tecting preeclampsia and effecting delivery, thereby
preventing the development of eclampsia and its con-
sequences. Eclampsia still occurs and, as will become
apparent, is often not preventable and therefore, does
not necessarily represent “a grievous failure of care.”
If we were able to prevent preeclampsia, eclampsia
would not become an issue. Unfortunately, we are un-
able to do this. Recent attempts with low dose aspirin
and calcium supplementation have not been success-
ful. If we cannot prevent preeclampsia, then our goal is
to identify it in a timely fashion through prenatal care.
The reason that prenatal visits are closer together in late
pregnancy is to help make this timely identification. If
all patients went through a progression from excessive
weight gain, to hypertension, to proteinuria, to severe
preeclampsia before seizures occurred and if this pro-
gression was slow and predictable, one could intervene
and potentially prevent nearly all cases of eclampsia.
Identification, hospitalization, magnesium sulfate, and
delivery are effective and most potential cases of eclamp-
sia are prevented. As we shall see, however, this is not
uniformly the case.
Does magnesium sulfate work?
It does. Magnesium sulfate was used empirically to
treat eclampsia and to prevent seizures in women with
preeclampsia for several decades before solid evi-
denced-based information was available. When
magnesium sulfate was compared with sedatives or
anticonvulsants in women with eclampsia, the rate of
recurrent seizures was approximately halved (23% to
9.4%—Obstet Gynecol 2005; 105:402-10). Maternal deaths
were also significantly reduced in those receiving mag-
nesium sulfate (3% versus 5%).
Other studies indicate that magnesium sulfate is ef-
fective in preventing eclampsia in women with severe
preeclampsia, but the overall rate of eclampsia is low.
In these studies, about 1% of the patients receiving mag-
nesium sulfate developed seizures versus 2 to 3% of
those receiving no therapy.
There have been small trials in women with mild
preeclampsia which do not demonstrate efficacy of
magnesium sulfate in seizure prophylaxis, however, the
number of patients enrolled in these studies is much
too small to permit one to draw any conclusions. Al-
though our practice is to utilize magnesium sulfate in
labor in women with mild preeclampsia, some make
the case that this may not be necessary.
Non-preventable eclampsia
Despite appropriate care to identify preeclampsia and
appropriate management of preeclampsia, eclampsia
still occurs. Why? Two decades ago, a study from Ten-
nessee looked at eclampsia and its preventability (Am J
Obstet Gynecol 1986; 154:581-6). One hundred seventy-
nine women were studied. In two-thirds of the cases
the eclampsia was considered to be preventable. In half
of these “preventable” cases, the fault lay with the pa-
tient (failure to attend prenatal care) and half the time,
the preventability reflected physician error. Overall,
however, in one-third of the cases, there was no appar-
ent preventability. Reasons included: 1) the apparently
abrupt onset of seizures in women who had obtained
timely prenatal care and in whom things were normal
at their last prenatal visits (in contrast to the slow pre-
dictable progression cited above, at time things moved
too quickly to be identified even by conscientious pre-
natal care); 2) onset prior to 20 weeks gestation; 3) onset
three days or more postpartum (when this report was
written, the later postpartum onset of preeclampsia/
eclampsia was not as appreciated as it is today—eclamp-
sia may occur as late as about 10 days postpartum); 4)
the occurrence in hospitalized women being observed
for mild preeclampsia (no specific blood pressure level
or degree of proteinuria is required for seizures to oc-
cur); and 5) seizures which occurred in women receiving
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magnesium sulfate. About half of those women who
had seizures on magnesium sulfate and in whom mag-
nesium levels were determined, had levels in the
therapeutic range (5-8 mg percent).
The Iowa Experience
At the time of perinatal program hospital visitations
over the past few years, we have looked at maternal
records with a discharge diagnosis of eclampsia.
Twenty-five records were reviewed. In three cases, the
diagnosis was uncertain and/or there was inadequate
information. The remaining 22 women with the diag-
nosis of eclampsia will now be considered.
One woman had recognized chronic hypertension. Six
of the 22 women were teenagers. In 15 cases, the pre-
eclampsia was considered mild or was of unknown
severity; severe preeclampsia was present in seven.
Fifteen patients presented antepartum, five intra-
partum, and two postpartum. Textbooks often describe
half of the cases of eclampsia as occurring intrapartum
or postpartum. I think our smaller percentage reflects
the fact that Iowa physicians are effectively identifying
women with preeclampsia, are treating with magnesium
sulfate in labor, and are effecting delivery. Eclampsia is,
therefore, prevented in these women.
No care deficiency or preventability was identified
in 10 cases; there were care deficiencies in my opinion
in 10 cases; and I remain uncertain in two patients. The
latter two women presented with hypertension, head-
ache, and no proteinuria. These women definitionally
had gestational hypertension (The Iowa Perinatal Letter,
volume 25, #2; 2004). I think it is important to distin-
guish gestational hypertension from preeclampsia (on
the basis of the absence or presence of proteinuria) and
regard preeclampsia as a much more significant pro-
cess. Perhaps, if the blood pressures are high enough
and headache is present, it would be prudent to give
magnesium sulfate even in the absence of proteinuria.
This was not done in these cases and seizures resulted.
I don’t think that I would have instituted magnesium
sulfate in these two women, but subsequent events in-
dicate it would have been the right thing to do.
The 10 cases without care deficiency or preventabil-
ity occurred in the following circumstances. In eight
women, things were fine at their last prenatal visits and
the timing of the next scheduled visits was appropri-
ate. One woman had a seizure six hours postpartum.
She was on magnesium sulfate for severe preeclamp-
sia. The final woman was admitted to rule out
preeclampsia and had apparent mild preeclampsia
when her seizure occurred.
Potential preventability
In 10 cases, the eclampsia was potentially prevent-
able. In three, the deficiency resided with the patient.
Two women had no prenatal care before presenting with
eclampsia at 30 and 35 weeks’ gestation. The third pa-
tient, 17 years old and carrying twins, was admitted to
the hospital with mild preeclampsia, but signed out
against medical advice. She returned after seizures oc-
curred.
Physician errors were involved in seven cases. Two
women with severe preeclampsia were in the hospital
for several hours without magnesium sulfate being
started. These women were distinctly hypertensive and
were symptomatic. It is true that often patients in the
hospital will settle down and if they are preterm, one
can at times treat the pregnancy expectantly, however,
if severe preeclampsia is present, it is prudent to begin
magnesium sulfate therapy on admission to the hospi-
tal. If things seem improved the next day and induction
of labor is not undertaken, one can discontinue the
magnesium therapy and reassess.
Three physician errors involved failure of magnesium
sulfate administration to women being induced for se-
vere preeclampsia. In one patient, the induction had
been underway for seven hours before magnesium sul-
fate therapy was instituted. She had a seizure soon
afterwards. Seizures can occur at any time during labor
in women with preeclampsia and, therefore, one should
not wait until “active labor” before beginning magne-
sium prophylaxis.
The final two cases of potential preventability oc-
curred in women with mild preeclampsia. One patient
was being treated as an outpatient and the second had
induction of labor performed, but magnesium sulfate
was not administered. As mentioned earlier, some con-
tend that magnesium sulfate therapy is not required in
labor in women with mild preeclampsia. In my opin-
ion, mild disease can go to severe disease very quickly
and in most cases I think women with mild preeclamp-
sia should receive magnesium sulfate in labor. This rapid
change in a patient’s status with mild preeclampsia is
the reason that I prefer to have women with mild preec-
lampsia admitted to the hospital in most cases. It is for
the patient with gestational hypertension that I think
outpatient care with close observation is appropriate.
Since eclampsia is associated with a real risk of ma-
ternal death and adverse perinatal outcome, one must
react to a patient’s complaint of headache during preg-
nancy or in the early puerperium in a conscientious
fashion. The questions that should be asked are: “What
is her blood pressure? Does she have proteinuria?”
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Magnesium administration
Magnesium sulfate is given intravenously as a 4 to 6
gram loading dose over 30 minutes followed by an in-
fusion usually of 2 grams per hour. The patient is placed
NPO. A Foley catheter is in place to monitor urinary
output, which should be at least 100 ml in every 4 hour
period. Deep tendon reflexes should be checked every
15 minutes during the loading dose and then on an
hourly basis. If the urine output is less than 100 ml in 4
hours or the respiratory rate is less than 12 per minute
or deep tendon reflexes are absent, a serum magnesium
level should be obtained, the magnesium sulfate infu-
sion should be stopped, and consideration should be
given to administering calcium gluconate depending
on the clinical circumstances. Calcium gluconate, given
intravenously, is the treatment for magnesium toxicity.
Ten milliliters of a 10% solution are given over a minute
or two. Magnesium sulfate is a safe drug if the patient
is carefully observed during its administration. Calcium
gluconate should be at the bedside.
Treatment of Eclampsia
If a seizure occurs under observation, the immediate
goal is to try to protect the woman. A padded tongue
blade can be inserted, the side rails raised, and the pa-
tient restrained. As the seizure subsides, one assesses
the airway, breathing, and circulation. The blood pres-
sure is checked, intravenous access is established, and
oxygen is administered. If magnesium sulfate is not
being infused, a 6 g load can be given over a shorter
time interval than usual (10-15 minutes), followed by
an infusion of 2 g per hour. If the patient is receiving
magnesium sulfate at the time of the initial seizure or if
there are recurrent seizures, an additional 2-4 g of mag-
nesium sulfate can be infused over 15 minutes.
Diastolics over 110 are treated with hydralazine or
labetalol (The Iowa Perinatal Letter, volume 25, #2; 2004).
Eclampsia means that delivery should be effected, but
in most cases it doesn’t mean immediately. During and
immediately after the seizure, the fetus may manifest
distress, but this is an ideal situation for in utero resus-
citation. As the mother improves with supportive care,
the fetus usually will too. If after 10-15 minutes the fetal
heart rate pattern is not improving, one must consider
placental abruption and move toward cesarean birth.
With an improved fetal heart rate pattern (the usual cir-
cumstance) and a relatively stable mother, one can
initiate induction of labor or perform a cesarean depend-
ing on presentation, gestational age, and status of the
cervix.
The future
The pathogenesis of preeclampsia is an area of active
investigation. Perhaps in the future, we will be able to
prevent preeclampsia.
At present in Iowa, most cases of eclampsia do not
reflect physician errors. Our goals should be to encour-
age prenatal care, to respect preeclampsia and consider
hospital admission, to liberally utilize magnesium sul-
fate in women with preeclampsia, and perhaps be more
aggressive in our response to the woman with gesta-
tional hypertension with high blood pressures,
especially if she complains of headache.
— Frank J. Zlatnik, M.D.
Iowa Maternal Mortality Review
The Maternal Mortality Study Committee of the Iowa
Medical Society has been in existence for more than half
a century and has formally reviewed maternal deaths
in the state on a periodic basis. The mechanism of re-
view and study committee recommendations appeared
in The Iowa Perinatal Letter in 1999 (volume 20, #4). Fol-
lowing a subsequent meeting, four maternal death case
histories were presented in 2003 (volume 24, #1).
The committee met in April 2005, and reviewed 10
maternal deaths from October 2000 to October 2004.
There were 6 “obstetric” maternal deaths and 4 “non-
obstetric” maternal deaths. Eight of the deaths were
judged to be non-preventable. In the other 2 cases, there
was insufficient information to make a judgment. One
of these involved a woman with postpartum hemor-
rhage (these deaths are often preventable) and the
second involved a case of peripartum cardiomyopathy
(these deaths are usually not preventable).
Although a sample size of only 10 precludes defini-
tive statements, it is of interest that 5 of the 10 women
were age 37 or older and that 3 of the 10 women were
black. There is certainly disproportionate representation
by age and race in this small sample.
In the past 20 years, the committee has reviewed 66
maternal deaths. Forty-nine of these were direct and
indirect obstetric deaths and 17 were non-obstetric
deaths. The latter included 4 women who died in mo-
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tor vehicle accidents, 3 homicides, 2 suicides, and 3
deaths from cardiac arrhythmia. The obstetric maternal
deaths are considered in the table.
Cause of Death Percent of Obstetric
Maternal Deaths
Pulmonary Embolism 24
Hemorrhage 16
Cardiomyopathy 12
Hypertension/Preeclampsia 10
Infection 8
Anesthetic Complications  4
Other 24
32nd Annual Iowa Conference on Perinatal Medicine
When: Tuesday, April 4 & Wed. April 5, 2006
Where: Des Moines Airport Holiday Inn
Fees: $135/2 days; $100/1 day
Highlighted Topics include:
• Comprehensive look at methamphetamine abuse and its
perinatal consequences
• Quality improvement in perinatal care
• Obstetric emergencies
• Breast-feeding issues
• Cardiac defects in the newborn
• PLUS many more
To receive a conference brochure and registration form please
contact Kathy Brogden @ 319-356-2637 or email katherine-
brogden@uiowa.edu
Review of the current cases brought up the issues of
screening for postpartum depression (The Iowa Perina-
tal Letter, volume 22, #1; 2001) and DVT prophylaxis at
cesarean delivery (The Iowa Perinatal Letter, volume 24,
#4; 2003). Shortness of breath is a significant and seri-
ous complaint. Those of us who practice obstetrics must
react to such a complaint by promptly seeing the pa-
tient, performing a careful history and physical
examination, and utilizing ancillary testing (e.g., pulse
oximetry, chest x-ray, spiral CT, echocardiography, etc.),
as indicated, in an attempt to make the correct diagno-
sis so that appropriate therapy can be promptly
instituted. It may be lifesaving.
— Frank J. Zlatnik, M.D.
